Plasma ATN biomarkers demonstrate significant equity gaps and differential transportability across demographic subgroups. The 12-percentage-point sensitivity disparity and education-dependent effect modification highlight barriers to equitable implementation. Population-based validation with fairness metrics should be prerequisite for clinical deployment.
Emmanuel Fle Chea (Tue,) studied this question.